Understanding Alzheimer’s – From discovery research to patient treatment
Positive results announced by Biogen, Anavex, and Lilly, along with Avanir's acquisition by Otsuka Pharma for US$3.5 billion have sparked renewed investor interest in Alzheimer’s drugs. Earlier this year, Axovant, a clinical-stage biotech focused on dementia treatments, pulled off one of the biggest biotech IPO in history with shares almost doubling on their first day of trade. These events reflect the enormous need to develop an effective treatment for Alzheimer’s disease. Actinogen Medical (ASX:ACW) invites Livewire readers to an investor event to learn more about Alzheimer’s disease and the companies working on a cure for Alzheimer’s. Please join us for a panel discussion and short presentations from leading industry, scientific and medical professionals including Eli Lilly, Alzheimer’s Australia and the Garvan Institute of Medical Research. This investor event will be held on Monday, October 12 at the Sofitel Hotel in Sydney from 4.30pm. Drinks and Canapés provided. To register your interest please click on this (VIEW LINK) . See the attached flyer for more information.
1 stock mentioned